611 related articles for article (PubMed ID: 17477372)
1. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
[TBL] [Abstract][Full Text] [Related]
2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
3. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
4. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H
Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269
[TBL] [Abstract][Full Text] [Related]
5. CaMKII(δ) regulates osteoclastogenesis through ERK, JNK, and p38 MAPKs and CREB signalling pathway.
Lu DZ; Dong W; Feng XJ; Chen H; Liu JJ; Wang H; Zang LY; Qi MC
Mol Cell Endocrinol; 2020 May; 508():110791. PubMed ID: 32173349
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of cantharidin on osteoclast differentiation and bone resorption.
Kim MH; Shim KS; Kim SH
Arch Pharm Res; 2010 Mar; 33(3):457-62. PubMed ID: 20361312
[TBL] [Abstract][Full Text] [Related]
7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
9. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
11. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
Shim KS; Ma CJ; Kim DS; Ma JY
J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
[TBL] [Abstract][Full Text] [Related]
12. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
13. Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways.
Kim BJ; Lee YS; Lee SY; Park SY; Dieplinger H; Yea K; Lee SH; Koh JM; Kim GS
J Endocrinol Invest; 2013 Nov; 36(10):876-82. PubMed ID: 23698732
[TBL] [Abstract][Full Text] [Related]
14. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Li L; Sapkota M; Kim SW; Soh Y
Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
[TBL] [Abstract][Full Text] [Related]
15. Chloroform extract of deer antler inhibits osteoclast differentiation and bone resorption.
Li YJ; Kim TH; Kwak HB; Lee ZH; Lee SY; Jhon GJ
J Ethnopharmacol; 2007 Sep; 113(2):191-8. PubMed ID: 17646068
[TBL] [Abstract][Full Text] [Related]
16. Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK.
Ang E; Liu Q; Qi M; Liu HG; Yang X; Chen H; Zheng MH; Xu J
J Cell Biochem; 2011 Jan; 112(1):89-97. PubMed ID: 20683903
[TBL] [Abstract][Full Text] [Related]
17. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
18. Amiloride inhibits osteoclastogenesis by suppressing nuclear factor-κB and mitogen-activated protein kinase activity in receptor activator of nuclear factor-κB-induced RAW264.7 cells.
Wang X; Zhu Y; Zheng S; Ni C; Zhao L; Liu C; Chen A; Xiao J
Mol Med Rep; 2015 May; 11(5):3451-6. PubMed ID: 25592168
[TBL] [Abstract][Full Text] [Related]
19. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway.
Yoon SH; Ryu Jy; Lee Y; Lee ZH; Kim HH
J Bone Miner Res; 2011 Jun; 26(6):1217-29. PubMed ID: 21611964
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]